Identification of Two Novel Pathogenic Mutations of GM1 Gangliosidosis in Japanese Domestic Shorthair Cats
World Small Animal Veterinary Association World Congress Proceedings, 2015
M. Kohyama; A. Yabuki; K. Kushida; O. Yamato
Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan

Introduction

GM1 gangliosidosis is a fatal, progressive, neurodegenerative lysosomal storage disease caused by mutations in the β-galactosidase (GLB1) gene. In feline GM1 gangliosidosis, a pathogenic mutation (c. 1448G > C) has been identified in the feline GLB1 gene and it has been found in Siamese, Korat and mixed-breed cats in several countries including Japan. Recently, two different families of feline GM1 gangliosidosis caused by each different novel mutation were found in Japanese domestic shorthair cats.

Objectives

To identify novel pathogenic mutations of the feline GLB1 gene.

Methods

Direct-sequence analysis and RT-PCR were performed to identify the causative mutation using genomic DNA and total RNA samples collected from affected, carrier and normal cats. The genotyping survey was carried out in the cat population in Japan using real-time PCR methods.

Results

Two novel pathogenic mutations in the feline GLB1 gene were identified in the different pedigrees of Japanese domestic shorthair cats. The genotyping survey revealed those two mutant alleles are not present in the population of about 1000 unaffected cats.

Conclusion

In this study, we successfully identified the two novel pathogenic mutations in feline GM1 gangliosidosis. The disease caused by these novel mutations will be very important not only in feline veterinary medicine but also as an animal model for the human disease.

  

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

M. Kohyama
Joint Faculty of Veterinary Medicine
Kagoshima University
Kagoshima, Japan


MAIN : Hereditary Diseases : Mutations of GM1 Gangliosidosis
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27